Ex­clu­sive: Brig­gs Mor­rison's Cross­bow Ther­a­peu­tics nabs $80M from MPM, Pfiz­er Ven­tures, Lil­ly in hunt for bet­ter can­cer drugs

Brig­gs Mor­ri­son is ready to take on can­cer with a new ar­se­nal of an­ti­bod­ies that his biotech hopes will be more pre­cise and tu­mor-killing than pre­vi­ous im­munother­a­pies.

Cross­bow Ther­a­peu­tics has reeled in an $80 mil­lion Se­ries A led by founder MPM BioIm­pact along­side Pfiz­er Ven­tures, with funds al­so com­ing from Eli Lil­ly, Po­laris Part­ners, BVF Part­ners and Mi­rae.

MPM’s Patrick Baeuer­le, Todd Fo­ley and Geral­dine Paulus found­ed the Cam­bridge, MA-based biotech to make new ther­a­pies that go af­ter the pep­tide-loaded ma­jor his­to­com­pat­i­bil­i­ty com­plex­es, or pMHCs, on can­cer cells. They’re specif­i­cal­ly go­ing af­ter in­tra­cel­lu­lar can­cer tar­gets, even se­cret­ed pro­teins, which Cross­bow hopes will broad­en the reach of an­ti­bod­ies, said Mor­ri­son, the CEO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER